Semaglutide

Ozempic and Wegovy both contain semaglutide but are FDA-approved for different indications at different doses. Ozempic is approved for type 2 diabetes management. Wegovy is approved specifically for chronic weight management in adults with obesity or a weight-related health condition. Using Ozempic off-label for weight loss — which became common during the semaglutide shortage period — is clinically different from using the weight-loss-indicated dose in Wegovy.

Both are highly effective. Clinical trial data shows tirzepatide (a dual GLP-1/GIP agonist) produces greater average weight loss than semaglutide (a single GLP-1 agonist) — approximately 20% versus 15% of body weight. However, the right medication depends on your individual metabolic profile, health history, insurance coverage, and clinical goals — not just which has the higher number in a trial.

Clinical data consistently shows that weight returns — often rapidly — when semaglutide is stopped if metabolic and behavioral change has not been established during treatment. This is why SPOKEmed builds every GLP-1 protocol around parallel coaching: structured nutrition habits, protein-first eating, sleep optimization, and stress management are developed alongside the medication so that when dosing is eventually reduced or stopped, patients have the physiological and behavioral foundation to maintain their results.